Trial of Combination Therapy to Treat COVID-19 Infection
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 300
Summary
- Conditions
- Corona Virus Infection
- Coronavirus Infection
- Coronavirus 19
- COVID
- COVID-19
- SARS-CoV Infection
- SARS COV2
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Double (Participant, Investigator)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
Patients in this trial will undergo treatment for 10 days with either a combination of therapies or placebo. They will then be followed for an additional 20 days.
Patients in this trial will undergo treatment for 10 days with either a combination of therapies or placebo. They will then be followed for an additional 20 days.
Tracking Information
- NCT #
- NCT04482686
- Collaborators
- Topelia Therapeutics
- Investigators
- Study Director: Sabine Hazan, MD ProgenaBiome Study Director: Thomas Borody, MD Topelia Therpeutics
Get Well Soon